Relapsed Follicular Lymphoma

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ADC Therapeutics
ADC TherapeuticsNJ - New Providence
1 program
1
Loncastuximab TesirinePhase 21 trial
Active Trials
NCT04699461TerminatedEst. Nov 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ADC TherapeuticsLoncastuximab Tesirine

Clinical Trials (1)

NCT04699461ADC TherapeuticsLoncastuximab Tesirine

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

Start: Nov 2021Est. completion: Nov 2022
Phase 2Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space